

Global Macular Degeneration Drug Pipeline Market Research Report 2023

<https://marketpublishers.com/r/G6F442F5CAE7EN.html>

Date: October 2023

Pages: 116

Price: US\$ 2,900.00 (Single User License)

ID: G6F442F5CAE7EN

Abstracts

This report aims to provide a comprehensive presentation of the global market for Macular Degeneration Drug Pipeline, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Macular Degeneration Drug Pipeline.

The Macular Degeneration Drug Pipeline market size, estimations, and forecasts are provided in terms of and revenue (\$ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Macular Degeneration Drug Pipeline market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Macular Degeneration Drug Pipeline companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

By Company

Amgen

Roche

Adverum Biotechnologies

AsclepiX Therapeutics

Bioeq AG

Sinocelltech

RemeGen

Grifols, S.A.

Kyowa Kirin

EyePoint Pharmaceutical

IVERIC Bio

Kodiak Sciences

Ribomic

Lineage Cell Therapeutics

Graybug Vision

CHABiotech

Shanghai Henlius Biotech

Bio-Thera Solutions

Alteogen

Outlook Therapeutics

Segment by Type

Gene therapy

Small molecules

Stem cell therapy

Gene therapies

Segment by Application

Hospital

Research Institute

Commercial

Other

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Macular Degeneration Drug Pipeline companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Macular Degeneration Drug Pipeline Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Gene therapy

1.2.3 Small molecules

1.2.4 Stem cell therapy

1.2.5 Gene therapies

1.3 Market by Application

1.3.1 Global Macular Degeneration Drug Pipeline Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital

1.3.3 Research Institute

1.3.4 Commercial

1.3.5 Other

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Macular Degeneration Drug Pipeline Market Perspective (2018-2029)

2.2 Macular Degeneration Drug Pipeline Growth Trends by Region

2.2.1 Global Macular Degeneration Drug Pipeline Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Macular Degeneration Drug Pipeline Historic Market Size by Region (2018-2023)

2.2.3 Macular Degeneration Drug Pipeline Forecasted Market Size by Region (2024-2029)

2.3 Macular Degeneration Drug Pipeline Market Dynamics

2.3.1 Macular Degeneration Drug Pipeline Industry Trends

2.3.2 Macular Degeneration Drug Pipeline Market Drivers

2.3.3 Macular Degeneration Drug Pipeline Market Challenges

2.3.4 Macular Degeneration Drug Pipeline Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Macular Degeneration Drug Pipeline Players by Revenue

3.1.1 Global Top Macular Degeneration Drug Pipeline Players by Revenue (2018-2023)

3.1.2 Global Macular Degeneration Drug Pipeline Revenue Market Share by Players (2018-2023)

3.2 Global Macular Degeneration Drug Pipeline Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Macular Degeneration Drug Pipeline Revenue

3.4 Global Macular Degeneration Drug Pipeline Market Concentration Ratio

3.4.1 Global Macular Degeneration Drug Pipeline Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Macular Degeneration Drug Pipeline Revenue in 2022

3.5 Macular Degeneration Drug Pipeline Key Players Head office and Area Served

3.6 Key Players Macular Degeneration Drug Pipeline Product Solution and Service

3.7 Date of Enter into Macular Degeneration Drug Pipeline Market

3.8 Mergers & Acquisitions, Expansion Plans

4 MACULAR DEGENERATION DRUG PIPELINE BREAKDOWN DATA BY TYPE

4.1 Global Macular Degeneration Drug Pipeline Historic Market Size by Type (2018-2023)

4.2 Global Macular Degeneration Drug Pipeline Forecasted Market Size by Type (2024-2029)

5 MACULAR DEGENERATION DRUG PIPELINE BREAKDOWN DATA BY APPLICATION

5.1 Global Macular Degeneration Drug Pipeline Historic Market Size by Application (2018-2023)

5.2 Global Macular Degeneration Drug Pipeline Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Macular Degeneration Drug Pipeline Market Size (2018-2029)

6.2 North America Macular Degeneration Drug Pipeline Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Macular Degeneration Drug Pipeline Market Size by Country (2018-2023)

6.4 North America Macular Degeneration Drug Pipeline Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7 EUROPE

7.1 Europe Macular Degeneration Drug Pipeline Market Size (2018-2029)

7.2 Europe Macular Degeneration Drug Pipeline Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Macular Degeneration Drug Pipeline Market Size by Country (2018-2023)

7.4 Europe Macular Degeneration Drug Pipeline Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 ASIA-PACIFIC

8.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size (2018-2029)

8.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2018-2023)

8.4 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 LATIN AMERICA

- 9.1 Latin America Macular Degeneration Drug Pipeline Market Size (2018-2029)
- 9.2 Latin America Macular Degeneration Drug Pipeline Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 9.3 Latin America Macular Degeneration Drug Pipeline Market Size by Country (2018-2023)
- 9.4 Latin America Macular Degeneration Drug Pipeline Market Size by Country (2024-2029)
- 9.5 Mexico
- 9.6 Brazil

10 MIDDLE EAST & AFRICA

- 10.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size (2018-2029)
- 10.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 10.3 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2018-2023)
- 10.4 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2024-2029)
- 10.5 Turkey
- 10.6 Saudi Arabia
- 10.7 UAE

11 KEY PLAYERS PROFILES

- 11.1 Amgen
 - 11.1.1 Amgen Company Detail
 - 11.1.2 Amgen Business Overview
 - 11.1.3 Amgen Macular Degeneration Drug Pipeline Introduction
 - 11.1.4 Amgen Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
 - 11.1.5 Amgen Recent Development
- 11.2 Roche
 - 11.2.1 Roche Company Detail
 - 11.2.2 Roche Business Overview
 - 11.2.3 Roche Macular Degeneration Drug Pipeline Introduction
 - 11.2.4 Roche Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
 - 11.2.5 Roche Recent Development
- 11.3 Adverum Biotechnologies
 - 11.3.1 Adverum Biotechnologies Company Detail

- 11.3.2 Adverum Biotechnologies Business Overview
- 11.3.3 Adverum Biotechnologies Macular Degeneration Drug Pipeline Introduction
- 11.3.4 Adverum Biotechnologies Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
- 11.3.5 Adverum Biotechnologies Recent Development
- 11.4 AsclepiX Therapeutics
 - 11.4.1 AsclepiX Therapeutics Company Detail
 - 11.4.2 AsclepiX Therapeutics Business Overview
 - 11.4.3 AsclepiX Therapeutics Macular Degeneration Drug Pipeline Introduction
 - 11.4.4 AsclepiX Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
 - 11.4.5 AsclepiX Therapeutics Recent Development
- 11.5 Bioeq AG
 - 11.5.1 Bioeq AG Company Detail
 - 11.5.2 Bioeq AG Business Overview
 - 11.5.3 Bioeq AG Macular Degeneration Drug Pipeline Introduction
 - 11.5.4 Bioeq AG Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
 - 11.5.5 Bioeq AG Recent Development
- 11.6 Sinocelltech
 - 11.6.1 Sinocelltech Company Detail
 - 11.6.2 Sinocelltech Business Overview
 - 11.6.3 Sinocelltech Macular Degeneration Drug Pipeline Introduction
 - 11.6.4 Sinocelltech Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
 - 11.6.5 Sinocelltech Recent Development
- 11.7 RemeGen
 - 11.7.1 RemeGen Company Detail
 - 11.7.2 RemeGen Business Overview
 - 11.7.3 RemeGen Macular Degeneration Drug Pipeline Introduction
 - 11.7.4 RemeGen Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
 - 11.7.5 RemeGen Recent Development
- 11.8 Grifols, S.A.
 - 11.8.1 Grifols, S.A. Company Detail
 - 11.8.2 Grifols, S.A. Business Overview
 - 11.8.3 Grifols, S.A. Macular Degeneration Drug Pipeline Introduction
 - 11.8.4 Grifols, S.A. Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)

- 11.8.5 Grifols, S.A. Recent Development
- 11.9 Kyowa Kirin
 - 11.9.1 Kyowa Kirin Company Detail
 - 11.9.2 Kyowa Kirin Business Overview
 - 11.9.3 Kyowa Kirin Macular Degeneration Drug Pipeline Introduction
 - 11.9.4 Kyowa Kirin Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
 - 11.9.5 Kyowa Kirin Recent Development
- 11.10 EyePoint Pharmaceutical
 - 11.10.1 EyePoint Pharmaceutical Company Detail
 - 11.10.2 EyePoint Pharmaceutical Business Overview
 - 11.10.3 EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Introduction
 - 11.10.4 EyePoint Pharmaceutical Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
 - 11.10.5 EyePoint Pharmaceutical Recent Development
- 11.11 IVERIC Bio
 - 11.11.1 IVERIC Bio Company Detail
 - 11.11.2 IVERIC Bio Business Overview
 - 11.11.3 IVERIC Bio Macular Degeneration Drug Pipeline Introduction
 - 11.11.4 IVERIC Bio Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
 - 11.11.5 IVERIC Bio Recent Development
- 11.12 Kodiak Sciences
 - 11.12.1 Kodiak Sciences Company Detail
 - 11.12.2 Kodiak Sciences Business Overview
 - 11.12.3 Kodiak Sciences Macular Degeneration Drug Pipeline Introduction
 - 11.12.4 Kodiak Sciences Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
 - 11.12.5 Kodiak Sciences Recent Development
- 11.13 Ribomic
 - 11.13.1 Ribomic Company Detail
 - 11.13.2 Ribomic Business Overview
 - 11.13.3 Ribomic Macular Degeneration Drug Pipeline Introduction
 - 11.13.4 Ribomic Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
 - 11.13.5 Ribomic Recent Development
- 11.14 Lineage Cell Therapeutics
 - 11.14.1 Lineage Cell Therapeutics Company Detail
 - 11.14.2 Lineage Cell Therapeutics Business Overview

- 11.14.3 Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Introduction
- 11.14.4 Lineage Cell Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
- 11.14.5 Lineage Cell Therapeutics Recent Development
- 11.15 Graybug Vision
 - 11.15.1 Graybug Vision Company Detail
 - 11.15.2 Graybug Vision Business Overview
 - 11.15.3 Graybug Vision Macular Degeneration Drug Pipeline Introduction
 - 11.15.4 Graybug Vision Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
 - 11.15.5 Graybug Vision Recent Development
- 11.16 CHABiotech
 - 11.16.1 CHABiotech Company Detail
 - 11.16.2 CHABiotech Business Overview
 - 11.16.3 CHABiotech Macular Degeneration Drug Pipeline Introduction
 - 11.16.4 CHABiotech Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
 - 11.16.5 CHABiotech Recent Development
- 11.17 Shanghai Henlius Biotech
 - 11.17.1 Shanghai Henlius Biotech Company Detail
 - 11.17.2 Shanghai Henlius Biotech Business Overview
 - 11.17.3 Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Introduction
 - 11.17.4 Shanghai Henlius Biotech Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
 - 11.17.5 Shanghai Henlius Biotech Recent Development
- 11.18 Bio-Thera Solutions
 - 11.18.1 Bio-Thera Solutions Company Detail
 - 11.18.2 Bio-Thera Solutions Business Overview
 - 11.18.3 Bio-Thera Solutions Macular Degeneration Drug Pipeline Introduction
 - 11.18.4 Bio-Thera Solutions Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
 - 11.18.5 Bio-Thera Solutions Recent Development
- 11.19 Alteogen
 - 11.19.1 Alteogen Company Detail
 - 11.19.2 Alteogen Business Overview
 - 11.19.3 Alteogen Macular Degeneration Drug Pipeline Introduction
 - 11.19.4 Alteogen Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
 - 11.19.5 Alteogen Recent Development

11.20 Outlook Therapeutics

11.20.1 Outlook Therapeutics Company Detail

11.20.2 Outlook Therapeutics Business Overview

11.20.3 Outlook Therapeutics Macular Degeneration Drug Pipeline Introduction

11.20.4 Outlook Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)

11.20.5 Outlook Therapeutics Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List Of Tables

LIST OF TABLES

- Table 1. Global Macular Degeneration Drug Pipeline Market Size Growth Rate by Type (US\$ Million): 2018 VS 2022 VS 2029
- Table 2. Key Players of Gene therapy
- Table 3. Key Players of Small molecules
- Table 4. Key Players of Stem cell therapy
- Table 5. Key Players of Gene therapies
- Table 6. Global Macular Degeneration Drug Pipeline Market Size Growth by Application (US\$ Million): 2018 VS 2022 VS 2029
- Table 7. Global Macular Degeneration Drug Pipeline Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029
- Table 8. Global Macular Degeneration Drug Pipeline Market Size by Region (2018-2023) & (US\$ Million)
- Table 9. Global Macular Degeneration Drug Pipeline Market Share by Region (2018-2023)
- Table 10. Global Macular Degeneration Drug Pipeline Forecasted Market Size by Region (2024-2029) & (US\$ Million)
- Table 11. Global Macular Degeneration Drug Pipeline Market Share by Region (2024-2029)
- Table 12. Macular Degeneration Drug Pipeline Market Trends
- Table 13. Macular Degeneration Drug Pipeline Market Drivers
- Table 14. Macular Degeneration Drug Pipeline Market Challenges
- Table 15. Macular Degeneration Drug Pipeline Market Restraints
- Table 16. Global Macular Degeneration Drug Pipeline Revenue by Players (2018-2023) & (US\$ Million)
- Table 17. Global Macular Degeneration Drug Pipeline Market Share by Players (2018-2023)
- Table 18. Global Top Macular Degeneration Drug Pipeline Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Macular Degeneration Drug Pipeline as of 2022)
- Table 19. Ranking of Global Top Macular Degeneration Drug Pipeline Companies by Revenue (US\$ Million) in 2022
- Table 20. Global 5 Largest Players Market Share by Macular Degeneration Drug Pipeline Revenue (CR5 and HHI) & (2018-2023)
- Table 21. Key Players Headquarters and Area Served
- Table 22. Key Players Macular Degeneration Drug Pipeline Product Solution and

Service

Table 23. Date of Enter into Macular Degeneration Drug Pipeline Market

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Macular Degeneration Drug Pipeline Market Size by Type (2018-2023) & (US\$ Million)

Table 26. Global Macular Degeneration Drug Pipeline Revenue Market Share by Type (2018-2023)

Table 27. Global Macular Degeneration Drug Pipeline Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 28. Global Macular Degeneration Drug Pipeline Revenue Market Share by Type (2024-2029)

Table 29. Global Macular Degeneration Drug Pipeline Market Size by Application (2018-2023) & (US\$ Million)

Table 30. Global Macular Degeneration Drug Pipeline Revenue Market Share by Application (2018-2023)

Table 31. Global Macular Degeneration Drug Pipeline Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 32. Global Macular Degeneration Drug Pipeline Revenue Market Share by Application (2024-2029)

Table 33. North America Macular Degeneration Drug Pipeline Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 34. North America Macular Degeneration Drug Pipeline Market Size by Country (2018-2023) & (US\$ Million)

Table 35. North America Macular Degeneration Drug Pipeline Market Size by Country (2024-2029) & (US\$ Million)

Table 36. Europe Macular Degeneration Drug Pipeline Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 37. Europe Macular Degeneration Drug Pipeline Market Size by Country (2018-2023) & (US\$ Million)

Table 38. Europe Macular Degeneration Drug Pipeline Market Size by Country (2024-2029) & (US\$ Million)

Table 39. Asia-Pacific Macular Degeneration Drug Pipeline Market Size Growth Rate by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 40. Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2018-2023) & (US\$ Million)

Table 41. Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2024-2029) & (US\$ Million)

Table 42. Latin America Macular Degeneration Drug Pipeline Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 43. Latin America Macular Degeneration Drug Pipeline Market Size by Country (2018-2023) & (US\$ Million)

Table 44. Latin America Macular Degeneration Drug Pipeline Market Size by Country (2024-2029) & (US\$ Million)

Table 45. Middle East & Africa Macular Degeneration Drug Pipeline Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 46. Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2018-2023) & (US\$ Million)

Table 47. Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2024-2029) & (US\$ Million)

Table 48. Amgen Company Detail

Table 49. Amgen Business Overview

Table 50. Amgen Macular Degeneration Drug Pipeline Product

Table 51. Amgen Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)

Table 52. Amgen Recent Development

Table 53. Roche Company Detail

Table 54. Roche Business Overview

Table 55. Roche Macular Degeneration Drug Pipeline Product

Table 56. Roche Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)

Table 57. Roche Recent Development

Table 58. Adverum Biotechnologies Company Detail

Table 59. Adverum Biotechnologies Business Overview

Table 60. Adverum Biotechnologies Macular Degeneration Drug Pipeline Product

Table 61. Adverum Biotechnologies Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)

Table 62. Adverum Biotechnologies Recent Development

Table 63. AsclepiX Therapeutics Company Detail

Table 64. AsclepiX Therapeutics Business Overview

Table 65. AsclepiX Therapeutics Macular Degeneration Drug Pipeline Product

Table 66. AsclepiX Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)

Table 67. AsclepiX Therapeutics Recent Development

Table 68. Bioeq AG Company Detail

Table 69. Bioeq AG Business Overview

Table 70. Bioeq AG Macular Degeneration Drug Pipeline Product

Table 71. Bioeq AG Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)

Table 72. Bioeq AG Recent Development

Table 73. Sinocelltech Company Detail

Table 74. Sinocelltech Business Overview

Table 75. Sinocelltech Macular Degeneration Drug Pipeline Product

Table 76. Sinocelltech Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)

Table 77. Sinocelltech Recent Development

Table 78. RemeGen Company Detail

Table 79. RemeGen Business Overview

Table 80. RemeGen Macular Degeneration Drug Pipeline Product

Table 81. RemeGen Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)

Table 82. RemeGen Recent Development

Table 83. Grifols, S.A. Company Detail

Table 84. Grifols, S.A. Business Overview

Table 85. Grifols, S.A. Macular Degeneration Drug Pipeline Product

Table 86. Grifols, S.A. Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)

Table 87. Grifols, S.A. Recent Development

Table 88. Kyowa Kirin Company Detail

Table 89. Kyowa Kirin Business Overview

Table 90. Kyowa Kirin Macular Degeneration Drug Pipeline Product

Table 91. Kyowa Kirin Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)

Table 92. Kyowa Kirin Recent Development

Table 93. EyePoint Pharmaceutical Company Detail

Table 94. EyePoint Pharmaceutical Business Overview

Table 95. EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Product

Table 96. EyePoint Pharmaceutical Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)

Table 97. EyePoint Pharmaceutical Recent Development

Table 98. IVERIC Bio Company Detail

Table 99. IVERIC Bio Business Overview

Table 100. IVERIC Bio Macular Degeneration Drug Pipeline Product

Table 101. IVERIC Bio Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)

Table 102. IVERIC Bio Recent Development

Table 103. Kodiak Sciences Company Detail

Table 104. Kodiak Sciences Business Overview

- Table 105. Kodiak Sciences Macular Degeneration Drug Pipeline Product
- Table 106. Kodiak Sciences Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)
- Table 107. Kodiak Sciences Recent Development
- Table 108. Ribomic Company Detail
- Table 109. Ribomic Business Overview
- Table 110. Ribomic Macular Degeneration Drug Pipeline Product
- Table 111. Ribomic Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)
- Table 112. Ribomic Recent Development
- Table 113. Lineage Cell Therapeutics Company Detail
- Table 114. Lineage Cell Therapeutics Business Overview
- Table 115. Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Product
- Table 116. Lineage Cell Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)
- Table 117. Lineage Cell Therapeutics Recent Development
- Table 118. Graybug Vision Company Detail
- Table 119. Graybug Vision Business Overview
- Table 120. Graybug Vision Macular Degeneration Drug Pipeline Product
- Table 121. Graybug Vision Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)
- Table 122. Graybug Vision Recent Development
- Table 123. CHABiotech Company Detail
- Table 124. CHABiotech Business Overview
- Table 125. CHABiotech Macular Degeneration Drug Pipeline Product
- Table 126. CHABiotech Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)
- Table 127. CHABiotech Recent Development
- Table 128. Shanghai Henlius Biotech Company Detail
- Table 129. Shanghai Henlius Biotech Business Overview
- Table 130. Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Product
- Table 131. Shanghai Henlius Biotech Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)
- Table 132. Shanghai Henlius Biotech Recent Development
- Table 133. Bio-Thera Solutions Company Detail
- Table 134. Bio-Thera Solutions Business Overview
- Table 135. Bio-Thera Solutions Macular Degeneration Drug Pipeline Product
- Table 136. Bio-Thera Solutions Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)

Table 137. Bio-Thera Solutions Recent Development

Table 138. Alteogen Company Detail

Table 139. Alteogen Business Overview

Table 140. Alteogen Macular Degeneration Drug Pipeline Product

Table 141. Alteogen Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)

Table 142. Alteogen Recent Development

Table 143. Outlook Therapeutics Company Detail

Table 144. Outlook Therapeutics Business Overview

Table 145. Outlook Therapeutics Macular Degeneration Drug Pipeline Product

Table 146. Outlook Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US\$ Million)

Table 147. Outlook Therapeutics Recent Development

Table 148. Research Programs/Design for This Report

Table 149. Key Data Information from Secondary Sources

Table 150. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

- Figure 1. Global Macular Degeneration Drug Pipeline Market Size Comparison by Type (2023-2029) & (US\$ Million)
- Figure 2. Global Macular Degeneration Drug Pipeline Market Share by Type: 2022 VS 2029
- Figure 3. Gene therapy Features
- Figure 4. Small molecules Features
- Figure 5. Stem cell therapy Features
- Figure 6. Gene therapies Features
- Figure 7. Global Macular Degeneration Drug Pipeline Market Size Comparison by Application (2023-2029) & (US\$ Million)
- Figure 8. Global Macular Degeneration Drug Pipeline Market Share by Application: 2022 VS 2029
- Figure 9. Hospital Case Studies
- Figure 10. Research Institute Case Studies
- Figure 11. Commercial Case Studies
- Figure 12. Other Case Studies
- Figure 13. Macular Degeneration Drug Pipeline Report Years Considered
- Figure 14. Global Macular Degeneration Drug Pipeline Market Size (US\$ Million), Year-over-Year: 2018-2029
- Figure 15. Global Macular Degeneration Drug Pipeline Market Size, (US\$ Million), 2018 VS 2022 VS 2029
- Figure 16. Global Macular Degeneration Drug Pipeline Market Share by Region: 2022 VS 2029
- Figure 17. Global Macular Degeneration Drug Pipeline Market Share by Players in 2022
- Figure 18. Global Top Macular Degeneration Drug Pipeline Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Macular Degeneration Drug Pipeline as of 2022)
- Figure 19. The Top 10 and 5 Players Market Share by Macular Degeneration Drug Pipeline Revenue in 2022
- Figure 20. North America Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 21. North America Macular Degeneration Drug Pipeline Market Share by Country (2018-2029)
- Figure 22. United States Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 23. Canada Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. Europe Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 25. Europe Macular Degeneration Drug Pipeline Market Share by Country (2018-2029)

Figure 26. Germany Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 27. France Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. U.K. Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. Italy Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. Russia Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Nordic Countries Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Asia-Pacific Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. Asia-Pacific Macular Degeneration Drug Pipeline Market Share by Region (2018-2029)

Figure 34. China Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. Japan Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. South Korea Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. Southeast Asia Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 38. India Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 39. Australia Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 40. Latin America Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 41. Latin America Macular Degeneration Drug Pipeline Market Share by Country (2018-2029)

Figure 42. Mexico Macular Degeneration Drug Pipeline Market Size YoY Growth

(2018-2029) & (US\$ Million)

Figure 43. Brazil Macular Degeneration Drug Pipeline Market Size YoY Growth

(2018-2029) & (US\$ Million)

Figure 44. Middle East & Africa Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. Middle East & Africa Macular Degeneration Drug Pipeline Market Share by Country (2018-2029)

Figure 46. Turkey Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 47. Saudi Arabia Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 48. Amgen Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 49. Roche Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 50. Adverum Biotechnologies Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 51. AsclepiX Therapeutics Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 52. Bioeq AG Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 53. Sinocelltech Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 54. RemeGen Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 55. Grifols, S.A. Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 56. Kyowa Kirin Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 57. EyePoint Pharmaceutical Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 58. IVERIC Bio Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 59. Kodiak Sciences Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 60. Ribomic Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 61. Lineage Cell Therapeutics Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 62. Graybug Vision Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 63. CHABiotech Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 64. Shanghai Henlius Biotech Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 65. Bio-Thera Solutions Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 66. Alteogen Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 67. Outlook Therapeutics Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

I would like to order

Product name: Global Macular Degeneration Drug Pipeline Market Research Report 2023

Product link: <https://marketpublishers.com/r/G6F442F5CAE7EN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6F442F5CAE7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970